Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs Pyrotinib + Capecitabine in Pretreated HER2+ Metastatic Breast Cancer
NCT05424835Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in HER2-positive breast cancer, sponsored by Hengrui. Started Aug 2022; status: active, not recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05424835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05424835.